Clearmind Medicine Inc. Form 6-K Summary
Business Context and Reporting Period
Clearmind Medicine Inc., a foreign private issuer based in Vancouver, British Columbia, filed this Form 6-K on January 14, 2026. The filing incorporates a press release regarding the clinical development of its lead candidate, CMND-100.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress rather than financial performance.
Material Changes
The primary material event reported is the successful completion of treatment in all patients of the second cohort in the ongoing Phase I/IIa clinical trial for CMND-100.
Outlook and Management Commentary
Management, represented by CEO Adi Zuloff-Shani, highlighted the milestone of completing the second cohort treatment. The filing incorporates specific paragraphs of the press release into the company's Registration Statements on Form F-3 and Form S-8. No specific financial guidance or risk factors beyond the standard clinical trial context were detailed in the provided text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed safety and efficacy data from the second cohort.
- Confirm the timeline for the next cohort or interim data readout.
- Review the company's most recent Form 20-F for current cash runway and burn rate, as this 6-K contains no financial data.
- Check for any subsequent filings that may supersede the information incorporated into the Form F-3 and Form S-8 registration statements.